BioNTech says BNT113 plus pembrolizumab misses progression — free survival endpoint in AHEAD — MERIT trial

BioNTech disclosed first topline results from the AHEAD-MERIT Phase 2/3 trial of BNT113 with pembrolizumab in metastatic HPV16-positive head and neck cancer. The study missed its progression-free survival endpoint, weakening near-term prospects for the combination in this first-line setting. Overall survival remains the second dual primary endpoint, with results to be assessed in a future analysis as the trial continues. A statistically significant overall survival benefit would still qualify as a positive trial outcome under the pre-specified design. Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. BioNTech SE published the original content used to generate this news brief via (Ref. ID: 202610130645PRIMZONEFULLFEED1001277682) on October 13, 2026, and is solely responsible for the information contained therein. (C)